Trial Profile
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma. A Phase II Multicenter Study "BENTLY".
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- Acronyms BENTLY
- 08 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 22 Aug 2009 New trial record